Medtronic PLC $MDT Holdings Decreased by Phoenix Financial Ltd.

Phoenix Financial Ltd. decreased its holdings in shares of Medtronic PLC (NYSE:MDT) by 20.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,603 shares of the medical technology company’s stock after selling 11,981 shares during the quarter. Phoenix Financial Ltd.’s holdings in Medtronic were worth $4,609,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Bessemer Group Inc. grew its stake in Medtronic by 60.6% in the fourth quarter. Bessemer Group Inc. now owns 4,075,987 shares of the medical technology company’s stock valued at $391,539,000 after purchasing an additional 1,537,958 shares in the last quarter. AustralianSuper Pty Ltd grew its stake in Medtronic by 32.4% in the fourth quarter. AustralianSuper Pty Ltd now owns 216,362 shares of the medical technology company’s stock valued at $20,784,000 after purchasing an additional 53,006 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Medtronic by 6.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 664,425 shares of the medical technology company’s stock valued at $63,831,000 after purchasing an additional 38,671 shares in the last quarter. Arbejdsmarkedets Tillaegspension purchased a new position in Medtronic in the fourth quarter valued at about $22,428,000. Finally, Cornerstone Wealth Management LLC grew its stake in Medtronic by 2.2% in the fourth quarter. Cornerstone Wealth Management LLC now owns 14,668 shares of the medical technology company’s stock valued at $1,409,000 after purchasing an additional 320 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

MDT opened at $76.12 on Friday. The company has a market cap of $97.73 billion, a PE ratio of 21.20, a price-to-earnings-growth ratio of 1.83 and a beta of 0.62. The stock has a 50-day moving average of $84.76 and a 200-day moving average of $93.64. Medtronic PLC has a 52-week low of $74.40 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on MDT shares. Citigroup lowered their target price on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Mizuho lowered their target price on Medtronic from $125.00 to $120.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Evercore set a $106.00 target price on Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Jefferies Financial Group restated a “hold” rating and issued a $95.00 target price on shares of Medtronic in a research note on Thursday, April 23rd. Finally, JPMorgan Chase & Co. lowered their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $107.80.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).